Japan: Market for Other Medicaments For Therapeutic Or Prophylactic Uses 2024

Market Size for Other Medicaments For Therapeutic Or Prophylactic Uses in Japan

The Japanese market for other medicaments for therapeutic or prophylactic uses expanded modestly to $X in 2022, rising by X% against the previous year. Over the period under review, consumption, however, continues to indicate a resilient increase. Consumption of peaked at $X in 2020; afterwards, it flattened through to 2022.

Production of Other Medicaments For Therapeutic Or Prophylactic Uses in Japan

In value terms, production of other medicaments for therapeutic or prophylactic uses rose modestly to $X in 2022 estimated in export price. Overall, production, however, continues to indicate a resilient increase. The most prominent rate of growth was recorded in 2019 when the production volume increased by X%. Over the period under review, production of reached the maximum level at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Exports of Other Medicaments For Therapeutic Or Prophylactic Uses

Exports from Japan

In 2022, exports of other medicaments for therapeutic or prophylactic uses from Japan shrank notably to X tons, waning by X% against 2021. Over the period under review, exports recorded a deep setback. The most prominent rate of growth was recorded in 2021 with an increase of X%. Over the period under review, the exports of hit record highs at X tons in 2012; however, from 2013 to 2022, the exports stood at a somewhat lower figure.

In value terms, exports of other medicaments for therapeutic or prophylactic uses contracted sharply to $X in 2022. In general, exports saw a drastic downturn. The pace of growth was the most pronounced in 2016 when exports increased by X%. Over the period under review, the exports of reached the maximum at $X in 2012; however, from 2013 to 2022, the exports stood at a somewhat lower figure.

Exports by Country

Taiwan (Chinese) (X tons), China (X tons) and South Korea (X tons) were the main destinations of exports of other medicaments for therapeutic or prophylactic uses from Japan, with a combined X% share of total exports.

From 2012 to 2022, the biggest increases were recorded for Taiwan (Chinese) (with a CAGR of X%), while shipments for the other leaders experienced a decline.

In value terms, China ($X), Ireland ($X) and the United States ($X) appeared to be the largest markets for other medicaments for therapeutic or prophylactic uses exported from Japan worldwide, with a combined X% share of total exports.

Ireland, with a CAGR of X%, saw the highest growth rate of the value of exports, in terms of the main countries of destination over the period under review, while shipments for the other leaders experienced mixed trend patterns.

Export Prices by Country

In 2022, the average export price for other medicaments for therapeutic or prophylactic uses amounted to $X per ton, surging by X% against the previous year. Overall, the export price showed a strong increase. As a result, the export price attained the peak level and is likely to continue growth in the immediate term.

There were significant differences in the average prices for the major overseas markets. In 2022, amid the top suppliers, the country with the highest price was Ireland ($X,817 per ton), while the average price for exports to Taiwan (Chinese) ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to China (X%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Other Medicaments For Therapeutic Or Prophylactic Uses

Imports into Japan

In 2022, overseas purchases of other medicaments for therapeutic or prophylactic uses increased by X% to X tons, rising for the second year in a row after three years of decline. Overall, total imports indicated a tangible increase from 2012 to 2022: its volume increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, imports increased by X% against 2020 indices. The pace of growth was the most pronounced in 2017 with an increase of X% against the previous year. As a result, imports attained the peak of X tons. From 2018 to 2022, the growth of imports of remained at a lower figure.

In value terms, imports of other medicaments for therapeutic or prophylactic uses expanded notably to $X in 2022. Over the period under review, total imports indicated prominent growth from 2012 to 2022: its value increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, imports increased by X% against 2019 indices. The growth pace was the most rapid in 2014 with an increase of X% against the previous year. Imports peaked in 2022 and are expected to retain growth in years to come.

Imports by Country

In 2022, China (X tons) constituted the largest other medicaments for therapeutic or prophylactic uses supplier to Japan, with a X% share of total imports. Moreover, imports of other medicaments for therapeutic or prophylactic uses from China exceeded the figures recorded by the second-largest supplier, Norway (X tons), twofold. The United States (X tons) ranked third in terms of total imports with a X% share.

From 2012 to 2022, the average annual growth rate of volume from China stood at X%. The remaining supplying countries recorded the following average annual rates of imports growth: Norway (X% per year) and the United States (X% per year).

In value terms, the United States ($X), China ($X) and Norway ($X) were the largest other medicaments for therapeutic or prophylactic uses suppliers to Japan, together accounting for X% of total imports.

In terms of the main suppliers, the United States, with a CAGR of X%, saw the highest growth rate of the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The average import price for other medicaments for therapeutic or prophylactic uses stood at $X per ton in 2022, increasing by X% against the previous year. Over the last decade, it increased at an average annual rate of X%. The most prominent rate of growth was recorded in 2018 an increase of X%. Over the period under review, average import prices hit record highs in 2022 and is expected to retain growth in the near future.

There were significant differences in the average prices amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was the United States ($X per ton), while the price for the Netherlands ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Italy (X%), while the prices for the other major suppliers experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :